Abstract
Multidrug-resistance (MDR) is the major reason for failure of cancer therapy. ATP-binding cassette (ABC) transporters contribute to drug resistance via ATP-dependent drug efflux. P-glycoprotein (Pgp), which is encoded by MDR1 gene, confers resistance to certain anticancer agents. The development of agents able to modulate MDR mediated by Pgp and other ABC transporters remained a major goal for the past 20 years. The calcium blocker verapamil was the first drug shown to be a modulator of Pgp, and since many different chemical compounds have been shown to exert the same effect in vitro by blocking Pgp activity. These included particularly immunosuppressors. Cyclosporin A (CSA) was the first immunosuppressor that have been shown to modulate Pgp activity in laboratory models and entered very early into clinical trials for reversal of MDR. The proof of reversing activity of CSA was found in phase II studies with myeloma and acute leukemia. In phase III studies, the results were less convincing regarding the response rate, progression-free survival, and overall survival, which were detected in advanced refractory myeloma. The non-immunosuppressive derivative PSC833 (valspodar) was subsequently developed. This compound showed tenfold higher potency in reversal of MDR mediated by Pgp. However, pharmacokinetic interactions required reductions in the dose of the concurrently administered anticancer agents. The pharmacokinetic interactions were likely because of decreased clearance of the anticancer agents, possibly as a result of Pgp inhibition in organs such as the gastrointestinal tract and kidney, as well as inhibition of cytochrome P450. Finally, CSA and PSC833 have been shown also to modulate the ceramide metabolism which stands as second messenger of anticancer agent-induced apoptosis. In fact, CSA and PSC833 are also able to respectively inhibit ceramide glycosylation and stimulate de novo ceramide synthesis. This could enhance the cellular level of ceramide and potentiate apoptosis induced by some anticancer agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Gottesman MM (1993) How cancer cells evade chemotherapy. Cancer Res 53:747–754
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972
Cano-Gauci DF, Riordan JR (1987) Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol 36:2115–2123
Silbermann MH, Boersma AW, Janssen AL et al (1989) Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance. Int J Cancer 44:722–726
Hait WN, Stein JM, Koletsky AJ, Harding MW, Handschumacher RE (1989) Activity of cyclosporin A and a non-immunosuppressive cyclosporin against multidrug resistant leukemic cell lines. Cancer Commun 1:35–43
Twentyman PR, Bleehen NM (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27:1639–1642
Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F et al (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226–4233
Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR (1988) Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun 153:959–966
Sonneveld P, Durie BG, Lokhorst HM et al (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 340:255–259
List AF, Spier C, Greer J et al (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652–1660
Sonneveld P, Suciu S, Weijermans P et al (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD)compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 115:895–902
List AF, Kopecky KJ, Willman CL et al (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98:3212–3220
Boote DJ, Dennis IF, Twentyman PR et al (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610–618
Giaccone G, Linn SC, Welink J et al (1997) A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3:2005–2015
Advani R, Saba HI, Tallman MS et al (1999) Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93:787–795
Fracasso PM, Westervelt P, Fears CL et al (2000) Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 18:1124–34
Baer MR, George SL, Dodge RK et al (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224–1232
Bates SE, Bakke S, Kang M et al (2004) A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 10:4724–4733
Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159–165
Burchenal JH, Robinson E, Johnston SF, Kushida MN (1950) The induction of resistance to 4-amino-N10-methyl-pteroylglutaminic acid in a strain of transmitted mouse leukemia. Science 111:116–117
Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466–483
Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162
Ueda K, Clark DP, Chen CJ et al (1987) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262:505–508
Riordan JR, Ling V (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 254:12701–1275
Riou JF, Naudin A, Lavelle F (1992) Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164–170
Greenberger LM, Lothstein L, Williams SS, Horwitz SB (1988) Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 85:3762–3766
Leier I, Jedlitschky G, Buchholz U et al (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807–27810
Honjo Y, Hrycyna CA, Yan QW et al (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6639
Wattel E, Solary E, Hecquet B et al (1999) Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol 457:35–46
Daenen S, van der Holt B, Verhoef GE et al (2004) Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. Leuk Res 28:1057–1067
Höllt V, Kouba M, Dietel M, Vogt G (1992) Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 43:2601–2608
Robert J, Jarry C (2003) Multidrug resistance reversal agents. J Med Chem 46:4805–4817
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234
Seelig A, Gatlik-Landwojtowicz E (2005) Inhibitors of multidrug efflux transporters: their membrane and protein interactions. Mini Rev Med Chem 5:135–151
Twentyman PR (1992) Cyclosporins as drug resistance modifiers. Biochem Pharmacol 43:109–117
Tanigawara Y, Okamura N, Hirai M et al (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line LLC-PK1. J Pharmacol Exp Ther 263:840–845
Wattel E, Solary E, Hecquet B et al (1998) Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 102:1015–1024
Hofmann J, Wolf A, Spitaler M et al (1992) Reversal of multidrug resistance by B859–35, a metabolite of B859–35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol 118:361–366
Minderman H, O’Loughlin KL, Pendyala L, Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10:1826–1834
Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595–4602
Zhou DC, Simonin G, Faussat AM, Zittoun R, Marie JP (1997) Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Leukemia 11:1516–1522
Dantzig AH, Shepard RL, Pratt SE III et al (2004) Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP-binding cassette (ABC) drug transporters. Biochem Pharmacol 67:1111–1121
Shepard RL, Cao J, Starling JJ, Dantzig AH (2003) Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103:121–125
Tang R, Faussat AM, Perrot JY et al (2008) Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 8:51
Martin C, Berridge G, Mistry P et al (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128:403–411
Walker J, Martin C, Callaghan R (2004) Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40:594–605
Evers R, Kool M, Smith AJ et al (2000) Inhibitory effect of the reversal agents V-104, GF120918 and pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83:366–374
van Zuylen L, Sparreboom A, van der Gaast A et al (2000) The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 6:1365–1371
van Zuylen L, Sparreboom A, van der Gaast A et al (2002) Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 38:1090–1099
Pierré A, Dunn TA, Kraus-Berthier L et al (1992) In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs 10:137–148
Punt CJ, Voest EE, Tueni E et al (1997) Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. Br J Cancer 76:1376–1381
Vastag B (2000) Almost serendipity: alcoholism drug reverses drug resistance in vitro. J Natl Cancer Inst 92:864–865
Venne A, Li S, Mandeville R, Kabanov A, Alakhov V (1996) Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56:3626–3629
Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T (1993) Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077–6080
Shirai A, Naito M, Tatsuta T et al (1994) Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim Biophys Acta 1222:400–404
Schramm U, Fricker G, Wenger R, Miller DS (1995) P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. Am J Physiol 268:F46–F52
Stein WD (1997) Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 77:545–590
Litman T, Zeuthen T, Skovsgaard T, Stein WD (1997) Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1361:159–168
Merlin JL, Guerci A, Marchal S et al (1994) Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84:262–269
Merlin JL, Guerci AP, Marchal S et al (1998) Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia. Br J Haematol 103:480–487
Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP (1998) Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91:4480–4488
Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP (1999) Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94:1046–1056
Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411–424
Bates SE (2002) Solving the problems of multidrug-resistance: ABC transporters in clinical oncology. In: Holland IB, Cole SP, Kuchler K et al (eds) ABC proteins: from bacteria to man. Elsevier Science, London, pp 359–391
Beketic-Oreskovic L, Duran GE et al (1995) Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87:1593–1602
Cocker HA, Tiffin N, Pritchard-Jones K, Pinkerton CR, Kelland LR (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 7:3193–3198
Levade T, Jaffrezou JP (1999) Signalling sphingomyelinases: which, where, how and why ? Biochim Biophys Acta 1438:1–17
Sietsma H, Veldman RJ, Kok JW (2001) The involvement of sphingolipids in multidrug resistance. J Membr Biol 181:153–162
Perry DK (2000) The role of de novo ceramide synthesis in chemotherapy-induced apoptosis. Ann N Y Acad Sci 905:91–96
Mandon EC, Ehses I, Rother J, van Echten G, Sandhoff K (1992) Subcellular localization and membrane topology of serine palmitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-acyltransferase in mouse liver. J Biol Chem 267:11144–11148
Michel C, van Echten-Deckert G (1997) Conversion of dihydroceramide to ceramide occurs at the cytosolic face of the endoplasmic reticulum. FEBS Lett 416:153–155
Hannun YA, Luberto C, Argraves KM (2001) Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 40:4893–4903
Michel C, van Echten-Deckert G, Rother J et al (1997) Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4, 5-trans-double bond of sphingosine at the level of dihydroceramide. J Biol Chem 272:22432–22437
Bose R, Verheij M, Haimovitz-Friedman A et al (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82:405–414
Turnbull KJ, Brown BL, Dobson PR (1999) Caspase-3-like activity is necessary but not sufficient for daunorubicin-induced apoptosis in Jurkat human lymphoblastic leukemia cells. Leukemia 13:1056–1061
Zhang J, Alter N, Reed JC et al (1996) Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc Natl Acad Sci USA 93:5325–5328
Olshefski RS, Ladisch S (2001) Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 93:131–138
Cabot MC, Giuliano AE, Han TY, Liu YY (1999) SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res 59:880–885
Myrick D, Blackinton D, Klostergaard J et al (1999) Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leuk Res 23:569–278
Mehta S, Blackinton D, Omar I et al (2000) Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 46:85–92
Cabot MC, Han TY, Giuliano AE (1998) The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. FEBS Lett 431:185–188
Goulding CW, Giuliano AE, Cabot MC (2000) SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett 149:143–151
Senchenkov A, Litvak DA, Cabot MC (2001) Targeting ceramide metabolism – a strategy for overcoming drug resistance. J Natl Cancer Inst 93:347–357
Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC (1999) Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 86:300–311
Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC (1999) Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol 15:541–546
Wang H, Giuliano AE, Cabot MC (2002) Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Mol Cancer Ther 1:719–726
Bezombes C, Maestre N, Laurent G et al (1998) Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J 12:101–109
Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC (1996) Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271:19530–19536
Liu YY, Han TY, Giuliano AE, Cabot MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274:1140–1146
Morjani H, Aouali N, Belhoussine R et al (2001) Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 94:157–165
Kok JW, Veldman RJ, Klappe K et al (2000) Differential expression of sphingolipids in MRP1 overexpressing HT29 cells. Int J Cancer 87:172–178
Lucci A, Cho WI, Han TY et al (1998) Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 18:475–480
Veldman RJ, Klappe K, Hinrichs J et al (2002) Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 16: 1111–1113
Lavie Y, Cao H, Volner A et al (1997) Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272:1682–1687
Lucci A, Giuliano AE, Han TY et al (1999) Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int J Oncol 15:535–540
Nicholson KM, Quinn DM, Kellett GL, Warr JR (1999) Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br J Cancer 81:423–430
Cabot MC, Giuliano AE, Volner A, Han TY (1996) Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett 394:129–131
Pommerenke E, Mattern J, Volm M (1994) Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo. J Cancer Res Clin Oncol 120:422–426
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Morjani, H., Madoulet, C. (2010). Immunosuppressors as Multidrug Resistance Reversal Agents. In: Zhou, J. (eds) Multi-Drug Resistance in Cancer. Methods in Molecular Biology, vol 596. Humana Press. https://doi.org/10.1007/978-1-60761-416-6_19
Download citation
DOI: https://doi.org/10.1007/978-1-60761-416-6_19
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-415-9
Online ISBN: 978-1-60761-416-6
eBook Packages: Springer Protocols